Agilent Technologies announced its participation in the American Association for Cancer Research, AACR, Annual Meeting. At the meeting, which will take place from April 5 to 10, 2024, in San Diego, CA, Agilent will highlight new cell analysis, genomics, digital pathology, and companion diagnostics solutions. Featured products and solutions that play a crucial role in advancing cancer research and diagnostics, will include: Agilent NovoCyte Opteon Spectral Flow Cytometer – The Agilent NovoCyte Opteon Spectral Flow Cytometer, is an advanced solution in spectral flow cytometry. Agilent Avida – Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample. Agilent SureSelect Cancer Custom panels – Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden and microsatellite instability, to custom tumor genomic profiling assays. Agilent SureSelect CD CiberMed Tissue and SureSelect CD CiberMed Heme panels – Agilent announces a new partnership with CiberMed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- China stimulus positive for GE HealthCare, tool companies, says Evercore ISI
- Early notable gainers among liquid option names on February 28th
- Agilent price target raised to $141 from $138 at BofA
- Agilent price target raised to $163 from $156 at TD Cowen
- Agilent price target raised to $143 from $138 at Baird
